Flea, Tick, And Heartworm Products Market Size, Trends, Forecast To 2033

(MENAFN- Straits Research) Introduction

Flea, tick, and heartworm products are essential medications designed to protect pets, primarily dogs and cats, from harmful parasites. Fleas and ticks can cause itching, allergic reactions, and transmit diseases like Lyme disease, while heartworms, spread through mosquito bites, can lead to severe heart and lung complications. These preventatives come in forms, including topical treatments, oral tablets, and collars, each offering different durations of protection.

Market Dynamics Increasing prevalence of vector-borne diseases drives the global market

The growing incidence of vector-borne diseases among pets is a major factor driving the demand for flea, tick, and heartworm prevention products. Urban expansion and climate change have contributed to the wider spread of disease-carrying vectors, increasing the risk of infections such as Lyme disease, ehrlichiosis, and heartworm disease.

As these threats become more prevalent, both pet owners and veterinarians are prioritizing preventive care to safeguard animal health.

• For instance, according to a February 2024 report by the Centers for Disease Control and Prevention (CDC), revised surveillance data from 2022 showed a 68.5% increase in reported Lyme disease cases in pets compared to the 2017–2019 period in the U.S.

This sharp rise in infections has significantly boosted awareness and adoption of effective flea, tick, and heartworm preventatives, reinforcing market expansion.

Expansion of pet insurance coverage for preventive care creates tremendous opportunities

As veterinary costs continue to rise, pet owners are actively seeking insurance plans that cover routine parasite prevention, making premium treatments more accessible and affordable. This trend is particularly notable in regions with growing pet insurance penetration, such as North America and Europe.

• For example, Trupanion and Nationwide Pet Insurance have expanded their policies to include flea, tick, and heartworm preventatives, encouraging more pet owners to opt for veterinarian-recommended solutions.

This shift not only improves overall pet health outcomes but also presents lucrative opportunities for manufacturers and veterinary providers, further propelling market growth.

Regional Analysis

North America dominates the global flea, tick, and heartworm products market , driven by high pet ownership rates, a well-established veterinary healthcare infrastructure, and strong awareness of vector-borne diseases. According to the 2024 American Pet Products Association (APPA) survey, 66% of U.S. households own a pet, ensuring sustained demand for both preventive and treatment solutions.

Moreover, the region benefits from a well-developed pet insurance sector, making premium parasite prevention more accessible. Regulatory oversight from agencies such as the U.S. Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) ensures product safety and efficacy, further strengthening consumer trust.

Key Highlights

• The global flea, tick, and heartworm products market size was valued at USD 7.21 billion in 2024 and is projected to grow from USD 7.82 billion in 2025 to reach USD 12.75 billion by 2033, exhibiting a CAGR of 6.3% during the forecast period (2025-2033).
• Based on product, the global market is segmented into diagnostic products and treatment products. The treatment products segment is the largest revenue contributor to the market.
• Based on parasites, the global flea, tick, and heartworm products market is segmented into external parasites and internal parasites. The external parasite segment is the largest revenue contributor to the market.
• Based on animals, the global flea, tick, and heartworm products market is segmented into canine, feline, and others. The canine segment is the largest revenue contributor to the market.
• Based on distribution channels, the global market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is the largest revenue contributor to the market.
• North America is the highest shareholder in the global market.

Competitive Players

Zoetis Services LLC

Boehringer Ingelheim

Merck & Co. Inc.

Virbac

Elanco

Ceva

Sergeant's

Adams

Bionote Inc.

Secure Diagnostics Pvt. Ltd.

iNtRON Biotechnology

PetIQ LLC.

The Hartz Mountain Corporation

Neogen Corporation

Recent Developments

• In January 2024, Merck Animal Health, known as MSD Animal Health outside the U.S. and Canada, secured European Commission (EC) approval for BRAVECTO (fluralaner) 150 mg/ml powder and solvent for suspension for injection in dogs. This product rapidly eliminates fleas (Ctenocephalides felis and Ctenocephalides canis) while offering extended tick protection.

Segmentation

By Product

Diagnostic Products

Test Kits

Consumables

Treatment Products

Spot on

Oral pills/Chewable

Spray

Shampoo

Others

By Parasite

External Parasite

Internal Parasite

By Animal

Canine

Feline

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Regions

North America

Europe

Asia-Pacific

Central & South America

The Middle East and Africa

MENAFN27032025004597010339ID1109362947